Log in to save to my catalogue

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-cont...

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-cont...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1544017031

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background In preclinical studies, davunetide promoted microtubule stability and reduced tau phosphorylation. Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP. We assessed the safety and efficacy of davunetide in patients with PSP. Methods In a double-blind, parallel group, pha...

Alternative Titles

Full title

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1544017031

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1544017031

Other Identifiers

ISSN

1474-4422

E-ISSN

1474-4465

DOI

10.1016/S1474-4422(14)70088-2

How to access this item